Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.41 |
| ▸ | PGR | P06401 | 4/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.36 |
| ▸ | MAT2A | P31153 | 1/20 | 0.35 |
| ▸ | ESRRA | P11474 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4751633 | 0.88 | AR (0.41) | ARPGRSCN9ASLC22A12ESRRA | |
| SCHEMBL4105432 | 0.86 | AR (0.38) | ARSLC22A12MAT2AESRRA | |
| SCHEMBL4104449 | 0.80 | PGR (0.40) | PGRMAT2AJAK2JAK1JAK3 | |
| SCHEMBL4752256 | 0.78 | AR (0.39) | ARPGRHPGD | |
| SCHEMBL509046 | 0.77 | KCNH2 (0.45) | MAT2ACYP2C19 | |
| SCHEMBL4109832 | 0.75 | ENPP3 (0.39) | ARSLC22A12MAT2AESRRA | |
| SCHEMBL4105032 | 0.74 | LRRK2 (0.37) | MAT2ACYP1A2CYP2C19 | |
| SCHEMBL4751277 | 0.74 | AR (0.40) | ARSLC22A12ESRRA | |
| SCHEMBL17671340 | 0.70 | LRRK2 (0.41) | MAT2A | |
| SCHEMBL10250882 | 0.70 | KCNH2 (0.36) | MAT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099209-A1 | Compounds Useful in Therapy | PFIZER INC | 2009-04-16 | — | — | US | disclosed |
| US-7482375-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1874732-A1 | PYRAZOLE DERIVATIVES AS PROGESTERONE RECEPTOR ANTAGONISTS | Pfizer Limited (GB) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006111856-A1 | PYRAZOLE DERIVATIVES AS PROGESTERONE RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 2006-10-26 | — | — | WO | disclosed |
| US-20060241125-A1 | Compounds useful in therapy | BRADLEY PAUL A | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241125-A1 | Compounds useful in therapy | CBR3, GPER1, CBR1 | AR 387/4885PGR 57/4885SCN9A 584/4885 |
| US-20090099209-A1 | Compounds Useful in Therapy | CBR3, CBR1, GPER1 | AR 400/4885PGR 87/4885SCN9A 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.